Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Hinge Bio Enters License and Collaboration Agreement with Kyorin Pharmaceutical for Autoimmune Disease Treatment in Japan.

Oct 01, 2025•9 months ago

Contract Type

agreement

BurlingameBiotechnologyHealth CareTherapeutics

Description

Hinge Bio has signed a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. to develop the therapeutic HB2198 in Japan for autoimmune diseases, starting with Systemic Lupus Erythematosus. The agreement includes a $10 million upfront payment and up to $95 million in milestone payments for further developments.

Company Information

Company

Hinge Bio

Location

863 MITTEN ROAD, SUITE 100L

Burlingame, California, United States

About

Hinge Bio is a privately held biotechnology company leveraging its powerful GEM-DIMER™ platform to develop therapeutics that address the problems of inadequate efficacy, resistance and side effects. The GEM-DIMER platform creates multivalent, multispecific antibody-based therapeutics that bind their targets in a novel manner allowing for dramatically enhanced biological activity and unique functionality. The GEM-DIMER technology was invented by Hinge Bio's Chief Scientific Officer, Daniel Capon, Ph.D., who previously was the first to clone and express recombinant Factor VIII (Genentech) and invented Fc-fusion proteins (Genentech) as well as chimeric antigen receptors for T cell therapy/CAR-T (Cell Genesys). Dr. Capon also holds patents on the XenoMouse for the production of fully human antibodies (Abgenix) and the PhenoSense drug susceptibility and resistance test (Monogram Biosciences/LabCorp).

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Hinge Bio's next move

Learn about Strategic plan

Agreement Insights

Based on industry data

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months